Perspective Therapeutics (CATX) vs OrthoPediatrics (KIDS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
OrthoPediatrics (KIDS) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 20.6% versus a loss of 31.1%. Over five years, CATX leads with a -57.1% price change compared with -65.6% for KIDS. OrthoPediatrics is the larger company by market cap ($565.3 million vs $303.6 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | KIDS |
|---|---|---|
| Share price | $2.66 | $21.65 |
| Market cap | $303.64M | $565.28M |
| 1-day change | -1.85% | -0.51% |
| YTD return | -3.27% | +21.90% |
| 1-year return | -31.09% | +20.61% |
| 5-year return | -57.10% | -65.60% |
| EPS (TTM) | $-1.33 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $26.74 |
| 52-week low | $1.96 | $14.42 |
| Distance from 52-week high | -56.82% | -19.04% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +362.03% | +25.73% |
| Average volume | 1.64M | 210.60K |
| Shares outstanding | 114.15M | 26.11M |
| Employees | 163 | 602 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KIDS has outperformed CATX by 51.7 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About OrthoPediatrics
KIDS stock →OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products.
Health Care · Medical/Dental Instruments · 602 employees
CATX vs KIDS FAQ
Which is bigger, Perspective Therapeutics or OrthoPediatrics?
OrthoPediatrics (KIDS) is larger, with a market capitalization of $565.28M compared with $303.64M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or KIDS?
KIDS returned +20.61% over the past 12 months, compared with -31.09% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and OrthoPediatrics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Perspective Therapeutics and Medical/Dental Instruments for OrthoPediatrics.